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Summary 
Background Information is scarce about the combined eﬀ ects on breast cancer incidence of low-penetrance genetic 
susceptibility polymorphisms and environmental factors (reproductive, behavioural, and anthropometric risk factors 
for breast cancer). To test for evidence of gene–environment interactions, we compared genotypic relative risks for 
breast cancer across the other risk factors in a large UK prospective study.
Methods We tested gene–environment interactions in 7610 women who developed breast cancer and 
10 196 controls without the disease, studying the eﬀ ects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 
2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, 
LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected 
information about ten established environmental risk factors (age at menarche, parity, age at ﬁ rst birth, 
breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, 
height, and alcohol consumption). 
Findings After allowance for multiple testing none of the 120 comparisons yielded signiﬁ cant evidence of a 
gene–environment interaction. By contrast with previous suggestions, there was little evidence that the genotypic 
relative risks were aﬀ ected by use of hormone replacement therapy, either overall or for oestrogen-receptor-positive 
disease. Only one of the 12 polymorphisms was correlated with any of the ten other risk factors: carriers of the 
high-risk C allele of MAP3K1-rs889312 were signiﬁ cantly shorter than non-carriers (mean height 
162·4 cm [95% CI 162·1–162·7] vs 163·1 cm [162·9–163·2]; p=0·01 after allowance for multiple testing).
Interpretation Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary 
signiﬁ cantly with these ten established environmental risk factors.
Funding Cancer Research UK and the UK Medical Research Council.
Introduction
Genome-wide association studies,1–6 together with analyses 
of speciﬁ c candidate polymorphisms,7,8 have identiﬁ ed 
several low-penetrance breast cancer susceptibility loci. 
Little is known about how the associated relative risks are 
aﬀ ected by the established reproductive, behavioural, and 
anthropometric risk factors for breast cancer (here referred 
to collectively as environmental factors, although some, 
such as height, are in part genetically determined). Of the 
few results published so far,9–13 some have suggested 
possible interactions between the eﬀ ects of FGFR2 
variants and use of hormone replacement therapy (HRT), 
but ﬁ ndings are inconsistent.11–13 Large-scale prospective 
data can help to assess any such gene–environment 
interactions. For 12 single nucleotide polymorphisms 
(SNPs) previously associated with the disease we compared 
relative risks for breast cancer across categories of ten 
established environmental risk factors14 in a large 
prospective UK cohort.
Methods
Participants
During 1996–2001, 1·3 million middle-aged women (mean 
age 56 years [SD 5]) who had been invited for routine 
screening for breast cancer at 66 National Health Service 
(NHS) screening centres in the UK were recruited into the 
Million Women Study and completed a questionnaire. 
The study design and methods are described elsewhere15 
and are available at the Million Women Study website. 
Study participants have a unique NHS number, and are 
routinely followed up for cause-speciﬁ c incident cancer 
and death via the NHS Central Registers. In 2005–08, 
women with breast cancer and randomly selected women 
without breast cancer were asked to participate in a genetic-
susceptibility study. Ethics approval for the work was 
granted from the Oxford and Anglia Multi-Centre Research 
and Ethics Committee and the Eastern Multi-Centre 
Research and Ethics Committee. 
Genotyping
Genotyping was done at the Centre National de Génotypage 
in Paris, France. Genotyping assays were designed and 
undertaken with use of the Taqman assay (Applied 
Biosystems, Foster City, CA, USA). Cases and controls 
were mixed for genotyping, and laboratory personnel were 
unaware of the case or control status of the samples. The 
genotyping success rate was at least 96% for each variant 
(range 96·3–98·8), and was 97% overall.
For the Million Women Study 
website see http://
millionwomenstudy.org
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Statistical analysis
We examined the association between ten environmental 
(ie, reproductive, behavioural, or anthropometric) risk 
factors for breast cancer and 12 SNPs (FGFR2-rs2981582, 
TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 
8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-
rs 1045485, LSP1-rs3817198, 5q-rs30099, TGFB1- rs1982073, 
and ATM-rs1800054), and whether these environ mental 
risk factors modiﬁ ed the relative risks of breast cancer 
associated with the SNPs. The ten environ mental risk 
factors studied were: age at menarche, parity, age at ﬁ rst 
birth, breastfeeding, menopausal status, age at meno-
pause, use of HRT, body-mass index, height, and alcohol 
consumption. Information about these factors was 
recorded prospectively at the time the women joined the 
study—ie, before the diagnosis of breast cancer in cases 
and at an equivalent time for controls. The eﬀ ects of most 
of the ten factors on breast cancer incidence have already 
been shown to be highly signiﬁ cant for the entire Million 
Women Study cohort.16–19
To describe the main eﬀ ect of each of the 12 SNPs on the 
relative risk for breast cancer, logistic regression models 
were applied, calculating the per-allele relative risks for the 
high-risk versus the low-risk allele, adjusted by age at 
recruitment (50–52, 53–55, 56–58, 59–61, and ≥62 years) 
and by ten regions in the UK (corresponding to UK cancer 
registration regions).
To study the associations between the genetic and 
environmental factors, we compared the means (for 
continuous variables) and proportions (for categorical 
variables) using ANOVA and conventional χ² tests of 
heterogeneity, respectively. Conventional p values are 
given but have been interpreted in view of the 120 (12 SNPs 
× ten other factors) comparisons made. With 120 tests, 
only an uncorrected p value of less than 0·0004 would be 
regarded as statistically signiﬁ cant.
For the main tests for gene–environment interaction, 
we compared the per-allele relative risks of breast cancer 
for each of the 12 SNPs across two levels of each of the ten 
other factors. For the continuous variables, women were 
divided into two groups of roughly equal size for the 
comparisons: age at menarche (<13 or ≥13 years); parity 
(nulliparous or parous); age at ﬁ rst birth (<25 or ≥25 years 
in parous women); age at menopause (<50 or ≥50 years, in 
postmenopausal never users of HRT); body-mass index 
(<25 or ≥25 kg/m²); height (<165 or ≥165 cm); and alcohol 
intake (<one or ≥one drink per day, as deﬁ ned previously18). 
For the categorical environmental factors (menopausal 
status, use of HRT, and breastfeeding), women were 
categorised as: premeno pausal/ peri menopausal or post-
menopausal never users of HRT; never/past or current 
users of HRT; and ever or never having breastfed in parous 
women). χ² tests were applied to assess heterogeneity in 
the per-allele relative risks of breast cancer by each 
environmental factor (assuming a linear relation of log 
risk with number of alleles). The per-allele relative risk 
estimates are presented together with conventional 
95% CIs and p values, but are interpreted in view of the 
120 tests for interaction. 
For continuous variables we also tested for interaction 
between the value of the variable and the per-allele log 
risk, and we repeated the categorical analyses with three 
rather than two groups. 
When results are presented as plots, the means, 
proportions, and relative risks are represented by squares 
(and the corresponding 95% CIs as lines), each with area 
inversely proportional to the variance of the logarithm of 
the values and thus providing an appropriate indication 
of the amount of statistical information included for that 
particular estimate. All statistical tests were two sided; 
analyses were done with Stata (version 10.0). 
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. RCT, DB, GKR, JG, and VB had 
full access to all the data in the study and all authors 
had ﬁ nal responsibility for the decision to submit for 
publication.
Cases 
(n=7610)
Controls 
(n=10 196)
p value*
Age at menarche (years) 12·9 (1·6) 12·9 (1·5) 0·5
Parity (% parous) 6537 (86%) 9000 (88%) <0·0001
Age at ﬁ rst birth in parous women (years) 24·9 (4·5) 24·6 (4·2) 0·0002
Breastfeeding (% of parous women who ever breastfed) 4036 (74%) 5626 (76%) 0·02
Menopausal status (% postmenopausal) 5906 (78%) 7789 (76%) 0·06
Age at natural menopause (years)† 49·9 (4·1) 49·5 (4·2) <0·0001
Current use of hormone replacement therapy† 2948 (50%) 3256 (42%) <0·0001
Body-mass index (kg/m2) 25·9 (4·4) 25·6 (4·2) <0·0001
Height (cm) 163·1 (6·6) 162·7 (6·6) <0·0001
Alcohol intake (g per day) 7·5 (8·2) 7·1 (7·7) 0·0005
Data are mean (SD) or number (%). Numbers do not always add up because of missing values. *For the eﬀ ect of each 
environmental risk factor on breast cancer risk (with the factor subdivided into two groups, as described in the 
Methods section). †Postmenopausal women only.  
Table: Baseline characteristics of breast cancer cases and controls
Relative risk of breast cancer
(95% CI) (per allele)
Frequency of
high-risk alleles
in controls
Gene/location
rs2981582 FGFR2/10q26 0·38(A) 1·22 (1·17–1·28) p<0·0001
rs3803662 TNRC9/16q12 0·26(A) 1·18 (1·13–1·24) p<0·0001
rs13387042        ··/2q35 0·50(A) 1·16 (1·11–1·21) p<0·0001
rs889312 MAP3K1/5q 0·28(C) 1·13 (1·08–1·19) p<0·0001
rs13281615         ··/8q24 0·40(G) 1·08 (1·04–1·13) p=0·0004
rs4666451         ··/2p 0·60(G) 1·08 (1·03–1·13) p=0·001
rs981782         ··/5p12 0·54(A) 1·07 (1·02–1·11) p=0·003
rs1045485 CASP8/2q35    0·87(G) 1·05 (0·99–1·12) p=0·12
rs3817198 LSP1/11p 0·32(C) 1·03 (0·98–1·07) p=0·3
rs30099     ··/5q 0·08(A) 1·02 (0·94–1·10) p=0·7
rs1982073 TGFB1/19q13 0·62(A) 1·02 (0·97–1·06) p=0·5
rs1800054 ATM/11q22    0·01(G) 1·01 (0·85–1·21) p=0·9
0·8 0·9 1·2 1·31·0 1·1
Figure 1: Summary of ﬁ ndings for 12 SNPs in 7610 women with breast cancer and 10 196 randomly selected 
controls without breast cancer
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Figure 2: Distribution of 
environmental risk factors 
for breast cancer by 
genotype
Figure shows means or 
proportions and 95% CIs. 
Numbers do not always add 
up because of missing values. 
*Never users of hormone 
replacement therapy. 
†Conventional p values are 
shown in the ﬁ gure; all 
p values are non-signiﬁ cant 
after adjustment for multiple 
testing, apart from that for 
rs889132 by height, when 
adjusted p=0·01. ‡Insuﬃ  cient 
data.
All (n=17 806)
rs2981582
GG (n=6282)
AG (n=8236)
AA (n=2890)
p value† 0·06 0·53 0·29 0·06 0·35 0·41 0·08 0·82 0·30 0·19
rs3803662
GG (n=9067)
AG (n=6943)
AA (n=1344)
p value† 0·02 0·02 0·13 0·44 0·79 0·02 0·33 0·18 0·76 0·04
rs13387042
GG (n=3995)
GA (n=8633)
AA (n=4641)
p value† 0·56 0·38 0·67 0·15 0·96 0·03 0·88 0·68 0·18 0·73
rs889312
AA (n=8625)
AC (n=7222)
CC (n=1446)
p value† 0·03 0·72 0·73 0·69 0·29 0·12 0·04 0·39 0·0001 0·12
rs13281615
AA (n=5976)
AG (n=8425)
GG (n=2924)
p value† 0·12 0·97 0·10 0·25 0·20 0·46 0·46 0·53 0·99 0·17
rs4666451
AA (n=2581)
AG (n=8305)
GG (n=6376)
p value† 0·06 0·04 0·22 0·36 0·98 0·60 0·53 0·36 0·87 0·12
rs981782
CC (n=3608)
AC (n=8692)
AA (n=5148)
p value† 0·55 0·37 0·56 0·28 0·74 0·55 0·10 0·45 0·10 0·27
rs1045485
CC (n=293)
CG (n=3911)
GG (n=13 286)
p value† 0·40 0·28 0·50 0·42 0·23 0·33 0·78 0·56 0·58 0·22
rs3817198
TT (n=8022)
CT (n=7621)
CC (n=1762)
p value† 0·29 0·43 0·88 0·07 0·53 0·32 0·89 0·66 0·35 0·05
rs30099
GG (n=14 326)
GA (n=2711)
AA (n=105)‡
p value† 0·99 0·26 0·99 0·67 0·73 0·51 0·70 0·24 0·96 0·93
rs1982073
GG (n=2491)
AG (n=7962)
AA (n=6740)
p value† 0·98 0·46 0·54 0·16 0·96 0·08 0·13 0·66 0·30 0·77
rs1800054
CC (n=17 084)
CG (n=500)
GG (n=4)‡
p value† 0·04 0·90 0·05 0·01 0·66 0·05 0·39 0·06 0·47 0·03
12·5 13·513 1·75 2·25223 25 2624 65 8575 50 807060
Mean or percentage (95% CI)
48 515049 35 5545 25 2726 162 164163 5 97
Age at 
menarche
(mean 
12·9 years)
Age at 
ﬁrst 
birth (mean 
24·7 years)
Number 
of children
(mean 
2·0)
Parous women 
who ever
breastfed
(mean 75%)
Post- 
meno-
pausal*
(mean 70%)
Age at 
natural
menopause*
(mean 49·6 years)
Current users 
of hormone
therapy
(mean 46%)
Body-mass 
index
(mean 
25·7 kg/m²)
Height
(mean 
162·9 cm)
Alcohol
(mean 
7·2 g 
per day)
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Results
7610 women with incident breast cancer and 
10 196 women without breast cancer were included in 
these analyses. The mean age of cases at cancer 
diagnosis was 60 years (SD 5·1). The table shows 
prospectively collected information about the charac-
teristics of cases and controls, recorded an average of 
4 years (SD 2·3) before cancer diagnosis for cases and at 
an equivalent time for controls. As expected from 
previously published results in this cohort,16–19 cases 
were, on average, less likely to be parous, were older at 
ﬁ rst birth, had a higher body-mass index, consumed 
more alcohol, and were more likely to be current users 
of HRT than controls. 
Figure 1 shows the high-risk allele frequency and the 
corresponding per-allele relative risks of breast cancer for 
each of the 12 SNPs. Results are arranged in order of 
magnitude of the per-allele relative risk, with the largest 
recorded for FGFR2-rs2981582, followed by TNRC9-
 rs 3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-
rs13281615, 2p-rs4666451, 5p12-rs981782, and CASP8-
rs1045485. The allele and genotype frequencies for each 
of the 12 loci in controls were similar to those reported 
for populations of European descent,1,3,7 and with no 
substantial deviations from Hardy-Weinberg proportions 
in the controls (p>0·1 for 11 comparisons and p=0·04 for 
one comparison).
We examined whether any of the ten environmental 
risk factors for breast cancer were related to any of the 
12 SNPs. Figure 2 shows the results, with SNPs ordered 
by magnitude of the per-allele relative risks. After 
allowance for multiple testing, there were no signiﬁ cant 
associations between 11 of the 12 polymorphisms and the 
ten environmental risk factors (ﬁ gure 2). For the 
12th polymorphism MAP3K1-rs889312, there was a 
signiﬁ cant association between the allele variants and 
height (p=0·0001, and after allowance for multiple tests 
with the Bonferroni correction, p=0·01). Homozygous 
carriers of the C allele, which is associated with an 
increased risk of breast cancer, were slightly shorter than 
were homozygous carriers of the AA allele (mean heights 
162·4 cm [95% CI 162·1–162·7] and 163·1 cm 
[162·9–163·2], respectively) with heterozygous AC 
carriers being of intermediate height (162·7 cm 
[162·6–162·9]).
Figure 3 shows the per-allele relative risks of breast 
cancer for each of the 12 polymorphisms by the ten 
environmental factors. Of the 120 separate statistical tests 
for gene–environment interaction only four yielded a 
p value less than 0·05, and none remained signiﬁ cant 
after allowance for multiple comparisons with the 
Bonferroni correction (ﬁ gure 3).
Of the multiple comparisons done, the strongest 
suggestion of a gene–environment interaction was 
between CASP8-rs1045485 and alcohol consumption; the 
per-allele relative risk of breast cancer for the common 
variant of CASP8-rs1045485 (ie, the high-risk G variant) 
was signiﬁ cantly greater in women who reported 
consuming one or more alcoholic drinks per day than in 
those consuming less alcohol (ﬁ gure 3); but after 
allowance for multiple testing this result was not 
signiﬁ cant. For three other interactions, conventional p 
values were of borderline signiﬁ cance: TNRC9 SNP 
rs3803662 for age at menopause (pheterogeneity=0·02); 
2q35-rs13387042 for age at menarche (pheterogeneity=0·04); 
and 5q-rs30099 for use of HRT (pheterogeneity=0·01). However, 
in view of the large numbers of tests done these could 
well be chance ﬁ ndings.
Relative risk (95% CI)
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HRT never/past 1·20 (1·10–1·31)
HRT current 1·23 (1·13–1·34)
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Figure 4: Per-allele relative risk (95% CI) of oestrogen-receptor-positive 
breast cancer by use of hormone replacement therapy in postmenopausal 
women
Conventional p values are shown in the ﬁ gure; all p values are non-signiﬁ cant 
after adjustment for multiple testing.
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The ﬁ ndings did not diﬀ er materially when women 
were subdivided into three rather than two groups on 
the basis of the environmental risk factors (webappendix 
p 1), when the environmental variables were treated as 
continuous, or when results for homozygous and 
heterozygous carriers of each SNP were examined 
separately (webappendix p 2).
Current use of HRT (but not past use) is associated 
with an increased risk of breast cancer in this cohort,16 
and current use has a far greater eﬀ ect on tumours that 
were oestrogen-receptor-positive (relative risk 2·44 
[95% CI 2·27–2·63]) than those that were oestrogen-
receptor-negative (1·32 [1·14–1·53]) (pheterogeneity<0·0001). 
Further more, some of the SNPs are more strongly 
related to oestrogen-receptor-positive than to oestrogen-
receptor-negative disease—eg, for FGFR2-rs2981582 the 
respective per-allele relative risks were 1·27 (1·21–1·34) 
and 1·01 (0·92–1·12) (pheterogeneity<0·0001). Although there 
was no strong evidence for gene–environment 
interaction by use of HRT on all types of breast cancer 
(ﬁ gure 3), we also studied oestrogen-receptor-positive 
disease separately. In a comparison of the per-allele 
relative risks for oestrogen-receptor-positive breast 
cancer there was again little evidence of heterogeneity 
by HRT use after allowance for multiple testing 
(ﬁ gure 4). Nor were there any signiﬁ cant interactions 
for oestrogen-receptor-positive disease or for all breast 
cancer when the current users were further subdivided 
by the type of HRT used—eg, for FGFR2 the per-allele 
relative risks associated with oestrogen-receptor-positive 
breast cancer were 1·15 (0·98–1·35) in current users of 
oestrogen-only HRT and 1·25 (1·12–1·40) in current 
users of oestrogen-progestin HRT (tests for interaction 
in current vs never/past users p=0·6 and p=0·6, 
respectively). The corresponding results by HRT type 
for all breast cancer were 1·09 (0·98–1·25) and 1·22 
(1·11–1·34), respectively (tests for interaction, p=0·1 and 
p=0·9, respectively). Numbers are too small to study 
gene–environment interactions for oestrogen-receptor-
negative breast cancer, since only about 20% of breast 
cancers are of this type.
A possible interaction between FGFR2 and birthweight 
was reported in a study of 693 women with breast cancer,20 
but there was no evidence of this in our data (per-allele 
relative risks of 1·21 [1·13–1·30] for birthweight <3·5 kg 
and 1·24 [1·12–1·38] for ≥3·5 kg; p=0·9).
Results were similar when the small number of women 
reporting non-white ethnic origin were excluded (28 cases 
[0·4%] and 51 controls [0·5%]; data not shown).
Discussion
In this large-scale and systematic examination of 
120 possible gene–environment interactions in 
7610 women with breast cancer, only four were con-
ventionally statistically signiﬁ cant (whereas six would be 
expected by chance alone) and none remained signiﬁ cant 
after appropriate allowance for the multiple tests that 
were done. Furthermore no strong relations between 
genotype and the environmental risk factors studied 
were detected, suggesting that the low-penetrance 
susceptibility loci investigated here do not generally 
aﬀ ect breast cancer risk through mechanisms involving 
these environmental factors.
The term gene–environment interactions is so widely 
used that we have retained it, even though several of the 
ten environmental risk factors for breast cancer 
(eg, height and body-mass index) have both environmental 
and genetic determinants. Selection of the ten 
environmental factors and of the 12 SNPs was based on 
reviews, meta-analyses, and results from genome-wide 
association studies published up to March, 2008 (when 
genotyping began).1,3,7,14 Since then an additional ﬁ ve 
genetic susceptibility regions have been identiﬁ ed, 
although the associated relative risks for breast cancer 
are not large.4–6 The only major environmental risk factor 
not studied here is postmenopausal hormone 
concentrations in blood,14,21 because these were not 
measured in this cohort.
The magnitude of the genotypic relative risks for 
breast cancer (shown in ﬁ gure 1) accord with other 
published results,1,3,7,9 with the largest risks noted for 
FGFR2-rs2981582 and TNRC9-rs3803662 (relative risks 
of about 1∙2 per allele) and 2q35-rs13387042 and 
MAP3K1-rs889312 (relative risks of about 1∙15 per 
allele). The four previous studies examining 
gene–environment interactions have been comparatively 
small (including 1049, 456, 1749, and 685 women with 
breast cancer10–13) and have generally examined only two 
loci (FGFR210–13 and MAP3K113). In our study there was 
more than 90% power, after allowing for multiple 
testing, to detect an interaction of at least 1·5 (on a 
multiplicative scale) between each of the risk factors and 
polymorphisms with a prevalence of at least 25% and a 
per-allele relative risk of at least 1·1. Thus, although 
there is suﬃ  cient power to assess reliably 
gene–environment interactions in the four or so SNPs 
most strongly associated with breast cancer, power to 
detect corresponding interactions with rarer, or low-risk, 
genetic variants is limited.
Most of the environmental factors are more strongly 
associated with breast cancer risk than are the genotypic 
factors that we studied. Current use of HRT is the 
strongest environmental risk factor in this cohort, 
agreement between the reported use of HRT and 
prescription data is excellent,22 and the associated relative 
risks are much greater than for any of the SNPs studied 
here. There is therefore greater statistical power to 
assess the gene–environment interaction for HRT use 
than for the other exposures. Nevertheless, there was 
little evidence for interactions between genotype, HRT 
use, and breast cancer risk. HRT has a substantially 
greater eﬀ ect on oestrogen-receptor-positive than on 
oestrogen-receptor-negative disease. However, even 
when analyses were restricted to oestrogen-receptor-
See Online for webappendix
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positive disease there was still little evidence for 
interactions (ﬁ gure 4). The FGFR2 gene is more strongly 
related to oestrogen-receptor-positive than to oestrogen-
receptor-negative disease and is the locus most 
commonly investigated by others with respect to use of 
HRT.11–13 The numbers of cases in previous studies were 
comparatively small, however, and a formal meta-
analysis of published results is precluded by the 
incompatible ways in which they have been presented.
For factors other than use of HRT, we did not replicate 
any of the reported gene–environment interactions.10,11,13 
For FGFR2, there has been one previous report of 
interactions with parity11 and with age at menarche,11 but 
these were not reproduced by us or by another study.13
Although there was no convincing evidence for 
gene–environment interactions, we did ﬁ nd that 
homozygous carriers of the high-risk C allele 
MAP3K1-rs889312 were on average 0·7 cm shorter than 
were homozygous carriers of the lower-risk A allele. The 
encoded enzyme is a serine/threonine kinase, which is 
implicated in early development and growth,23 but the 
association is in the opposite direction of that expected if 
this gene aﬀ ected breast cancer risk via its eﬀ ect on height. 
Taller women are at a slightly increased risk of breast 
cancer than are shorter women, but carriers of the high-
risk allele are slightly shorter than are carriers of the low-
risk allelles. Although a possible association between 
rs2981582 and rs3803662 genotypes and duration of 
breastfeeding has been reported previously,9 we found 
little evidence for such eﬀ ects.
Most of the women that we studied were 
postmenopausal, and we have no useful information 
about breast cancer risk in younger women. However, 
meta-analysis of the worldwide data for women whose 
breast cancer was diagnosed before age 50 years24 
showed little variation in familial risk by environmental 
risk factors.
Many statistical tests were done and, because there 
were few a-priori hypotheses, our ﬁ ndings are largely 
hypothesis generating. The function of most of the SNPs 
is unclear and future investigations might show them to 
be only markers of the true causal variants. Although 
our study is fairly large, with prospectively collected 
exposure data from one cohort, it still lacked power to 
assess moderate gene–environment interactions for all 
but the four or so SNPs most strongly related to breast 
cancer risk or to investigate interactions separately for 
causally distinct types of breast cancer, such as those 
with and without oestrogen receptors. Whereas 
thousands of cases were needed to characterise the main 
eﬀ ects of environmental factors and of genetic factors on 
breast cancer risk, tens of thousands of cases will be 
needed to assess reliably a comprehensive range of 
biologically plausible gene–environment interactions.
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